Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Corcept Therapeutics (CORT) over the last 11 years, with Q3 2025 value amounting to $14.1 million.

  • Corcept Therapeutics' Other Non-Current Liabilities rose 1000.23% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 1000.23%. This contributed to the annual value of $14.1 million for FY2024, which is 3664.5% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Other Non-Current Liabilities of $14.1 million as of Q3 2025, which was up 1000.23% from $15.7 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Other Non-Current Liabilities registered a high of $15.7 million during Q2 2025, and its lowest value of $403000.0 during Q2 2021.
  • For the 5-year period, Corcept Therapeutics' Other Non-Current Liabilities averaged around $8.4 million, with its median value being $10.0 million (2023).
  • In the last 5 years, Corcept Therapeutics' Other Non-Current Liabilities skyrocketed by 176.77% in 2021 and then soared by 212420.54% in 2022.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Other Non-Current Liabilities stood at $409000.0 in 2021, then soared by 2124.21% to $9.1 million in 2022, then increased by 13.3% to $10.3 million in 2023, then skyrocketed by 36.64% to $14.1 million in 2024, then increased by 0.34% to $14.1 million in 2025.
  • Its last three reported values are $14.1 million in Q3 2025, $15.7 million for Q2 2025, and $14.3 million during Q1 2025.